Live-cell imaging identifies cAMP microdomains regulating β-adrenoceptor-subtype-specific lipolytic responses in

Kirstie A De Jong1, Sandra Ehret2, Joerg Heeren2

  • 1Institute of Experimental Cardiovascular Research, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.

Cell Reports
|April 26, 2023
PubMed

Insights

White adipocytes use cAMP microdomains to control fat breakdown. In type 2 diabetes, these microdomains are dysregulated, causing lipotoxicity, but metformin can restore their function.

Area of Science:

  • Cell biology
  • Metabolic signaling
  • Endocrinology

Background:

  • Lipolysis is regulated by β-adrenergic receptor (β-AR)/cAMP signaling and phosphodiesterases (PDEs).
  • Type 2 diabetes involves triglyceride dysregulation and lipotoxicity.
  • Subcellular compartmentalization of signaling molecules is crucial for cellular function.

Purpose of the Study:

  • To investigate the role of subcellular cAMP microdomains in regulating lipolysis in human white adipocytes.
  • To examine cAMP/PDE dynamics in insulin resistance and type 2 diabetes.
  • To assess the therapeutic potential of targeting cAMP microdomains.

Main Methods:

  • Utilized a sensitive fluorescent biosensor for real-time, single-cell imaging of cAMP/PDE dynamics.
  • Studied human white adipocytes under basal and stimulated conditions.
  • Investigated the effects of insulin resistance and metformin treatment.

Main Results:

  • Identified distinct, receptor-associated cAMP microdomains in white adipocytes that compartmentalize cAMP signals.
  • Demonstrated that these microdomains differentially regulate lipolysis.
  • Observed dysregulation of cAMP microdomains in insulin resistance, contributing to lipotoxicity.
  • Showed that metformin can restore normal cAMP microdomain function.

Conclusions:

  • White adipocytes employ cAMP microdomains to precisely control lipolysis.
  • Dysregulation of these microdomains contributes to lipotoxicity in insulin resistance.
  • Targeting cAMP microdomains represents a potential therapeutic strategy for type 2 diabetes, with metformin showing efficacy.